Search Thermo Fisher Scientific
Explore CTS HSC media and reagents for cell therapy development and manufacturing
Hematopoietic stem/progenitor cells, or HSCs, are a promising cell type for the development of cell therapies. They can be derived from many sources, including mobilized peripheral blood, umbilical cord blood, bone marrow, or pluripotent stem cells, and can further differentiate into adult immune cells including T cells, NK cells, B cells, monocytes, and dendritic cells. In addition to their traditional use in bone marrow transplantation, HSCs are being investigated for use in cell and gene therapies to address blood disorders (leukemia, lymphoma) and other medical conditions.
Thermo Fisher Scientific has developed Gibco Cell Therapy Systems (CTS) products to address needs throughout the hematopoietic stem cell therapy workflow. These solutions aim to help facilitate the transition from discovery to commercial manufacturing. The company helps provide high-quality ancillary materials manufactured under Good Manufacturing Practices (GMP), helping ensure commercial scale production. These materials are extensively qualified, traceable, and accompanied by regulatory documentation.
- Scalable manufacturing under GMP conditions—CTS media and reagents are manufactured in conformity with GMP for medical devices, 21 CFR Part 820, and follow USP<1043> and Ph Eur 5.2.12, and the manufacturing sites are FDA-registered and ISO 13485- and/or ISO 9001-certified. The investment in rigorous product manufacturing helps ensure the consistency, reliability, and high quality of iPSC therapy reagents in combination with the ability to scale up and accommodate changing needs.
- Quality control testing and regulatory documentation—CTS media and reagents help minimize the risk of contamination and variability in research with extensive safety testing, including sterility, endotoxin, and mycoplasma. Full traceability for raw materials is also available, including Drug Master Files, Regulatory Support Files, and Certificates of Origin.
- Proven use from research to clinic—An extensive selection of serum-free, xeno-free, or animal origin-free formulations with cell therapy specific intended use statements and complementary research use reagents. Our CTS products have been used in over 200 clinical trials as well as in commercially approved cell therapies including FDA-approved CAR-T therapies and the first FDA-approved therapeutic cancer vaccine.
CTS StemPro-34 SF XenoFree Medium
The centerpiece of Thermo Fisher Scientific’s portfolio to support HSC therapy development is Gibco CTS StemPro-34 SF XenoFree Medium, a flexible, optimized medium for hematopoietic stem and progenitor cell applications. CTS StemPro-34 SF XenoFree Medium enables excellent expansion of CD34+ cells isolated from cord blood, bone marrow or mobilized peripheral blood compared to StemPro-34 Medium and competitors' HSC media solutions (Figures 1 and 2). Increased expansion and cell viability (Figure 3) allows users to decrease culture times and save on culture media. CTS StemPro-34 SF XenoFree Medium is available in both bottle and bioprocess container formats.
Figure 1. iPSC-derived iHSPCs (induced human stem/progenitor cells) differentiated in CTS StemPro-34 SF XenoFree Medium supplemented with PeproGMP cytokines show increased yields of relevant iHSPC phenotypes, enabling the user to reach target HSC concentrations in less time compared to cultures grown in StemPro-34 Medium. Fibroblast-derived iPSCs were differentiated in either CTS StemPro-34 SF XenoFree Medium or StemPro-34 Medium, in 6-well plates for 14 days. On Day 14 cell phenotype was determined by flow cytometry and cell counts and viability were determined by trypan blue dye exclusion and used to calculate yields of CD34+ CD43+, CD34+ CD45+ and total viable cells (normalized fold increase shown).
Figure 2. Fibroblast-derived iPSCs differentiated in CTS StemPro-34 SF XenoFree Medium supplemented with PeproGMP cytokines show increased yield of HSPCs when compared to fibroblast-derived iPSCs differentiated in competitor media. Fibroblast-derived iPSCs were differentiated in either CTS StemPro-34 SF XenoFree Medium or other commercially available HSC media, in 6-well plates for 14 days. On Day 14 cell phenotype was determined by flow cytometry, and cell counts and viability were determined by trypan blue dye exclusion and used to calculate yields of CD34+ CD43+, CD34+ CD45+ expressing cells and total viable cells (normalized fold increase shown).
Figure 3. CTS StemPro-34 SF XenoFree Medium enables excellent expansion of CD34+ cells isolated from cord blood, bone marrow or mobilized peripheral blood compared to StemPro-34 Medium, enabling the user to reach target HSC concentrations in less time compared to cultures grown in StemPro-34 Medium. CTS StemPro-34 SF XenoFree Medium enables excellent expansion of CD34+Lineage- cells compared to StemPro-34 Medium, with equivalent CD34+ Lineage- phenotype and viability. CD34+ cells isolated from cord blood (CB), bone marrow (BM) or mobilized peripheral blood (mPB) from 6 randomly selected donors were cultured for 6 days in multi-well plates. Both media were supplemented with SCF (100 ng/mL), IL-3 (50 ng/mL) and GM-CSF (25 ng/mL). Phenotype was determined by flow cytometry on Day 0 and Day 6, and cell counts and viability were determined by trypan blue dye exclusion. This data was used to calculate relative fold increase of CD34+LIN- and total viable cells (normalized fold increase shown).
HSC differentiation
CTS StemPro-34 SF XenoFree Medium
Gibco CTS StemPro-34 SFM Medium is a highly effective medium designed for the differentiation, growth and development of human hematopoietic cells in culture. This includes hematopoietic stem cells and progenitor cells sourced from bone marrow, neonatal cord blood, and peripheral blood.
Order CTS StemPro-34 SF XenoFree Medium
PeproGMP Recombinant Proteins
Gibco PeproTech and PeproGMP growth factors and cytokines for HSC culture
Thermo Fisher Scientific offers growth factors and cytokines in the Gibco PeproTech portfolio to effectively maintain and expand human HSCs.
iPSC differentiation
For products and services to support iPSC-derived cell therapy development, including reprogramming and stem cell culture, please visit our iPSC therapy solutions page.
Gene editing
CTS HIFi Cas9 Protein
Regulatory bodies like the FDA recognize the safety concerns of off-target cleavage events when using CRISPR-Cas9, particularly for therapeutics applications. To address these safety risks, there is a developed CTS HiFi Cas9 Protein, a GMP-manufactured high-fidelity Cas9 protein designed to significantly reduce off-target events while maintaining high editing efficiency. See the data.
- Significantly reduce off-target effects—>90% reduction in a broad range of cell types including primary immune cells
- Equivalent editing efficiency—Achieve the same high editing efficiency as CTS TrueCut Cas9 Protein, our wild-type protein designed for exceptional on-target editing efficiency
- Improved knock-in efficiency—Also offered in CTS HiFi Cas9 and CTS Xenon Genome Editing Buffer Kit to offer 2X improved knock-in efficiency
Order CTS HiFi Cas9 Protein
TrueGuide Synthetic gRNA
Invitrogen TrueGuide Synthetic gRNAs are ready-to-transfect CRISPR sgRNAs designed and validated to provide specific and high-efficiency knockout of your target gene. Search for your gene of choice to find predesigned TrueGuide synthetic gRNA.
CTS StemFlex Medium
CTS StemFlex Medium is a xeno-free medium designed for robust expansion of feeder-free pluripotent stem cells (PSCs). The optimized formulation supports stressful applications for translational and clinical research and offers a flexible feeding schedule. PSCs expanded in CTS StemFlex Medium maintain stable karyotype, pluripotency, and tri-lineage differentiation potential across multiple passages and cell lines. Learn more
CTS StemFlex Medium:
- Delivers reliable performance for gene editing and single cell passaging.
- Offers a flexible feeding schedule.
- Supports the transition from other adherent culture media.
- Facilitates regulatory filings with GMP manufacturing, traceability of raw materials, and regulatory documentation.
Order CTS StemFlex Medium
Adult immune cells
For solutions to support NK cell therapy development, please visit our NK cell therapy solutions page
For solutions to support T cell, DC, iMAC, and other adult immune cell therapy development, please visit our T and dendritic cell therapy solutions page
.jpg "CTS Rotea Counterflow Centrifugation System")
Intended use of the products mentioned on this page vary. For specific intended use statements please refer to the product label.